Vtama (tapinarof) cream is a prescription topical treatment FDA-approved for two inflammatory skin conditions: plaque psoriasis in adults and atopic dermatitis (eczema) in adults and children aged 2 and older. It works differently from steroids and other traditional topical treatments, making it a notable option for people managing chronic skin inflammation.
Two FDA-Approved Uses
Vtama was first approved in 2022 for plaque psoriasis, the most common form of psoriasis, which causes raised, scaly patches on the skin. In late 2024, the FDA expanded its approval to include atopic dermatitis, a condition marked by intense itching, redness, and dry or cracked skin. For psoriasis, the approval covers adults only. For atopic dermatitis, it covers adults and children as young as 2 years old.
The cream is applied once daily as a thin layer directly on affected skin. You apply it only to the areas with active patches or lesions, avoiding unaffected skin, and wash your hands afterward (unless you’re treating your hands). It is not meant for use around the eyes, inside the mouth, or internally.
How Vtama Works
Vtama belongs to a different drug class than topical steroids or calcineurin inhibitors. It activates a receptor in skin cells called the aryl hydrocarbon receptor, which plays a role in regulating inflammation and skin barrier function. When this receptor is switched on by tapinarof, it dials down the specific immune signals that drive both psoriasis and eczema. In psoriasis, those signals come from a branch of the immune system that produces inflammatory proteins like IL-17. In eczema, a different branch overproduces proteins like IL-4, IL-13, and IL-31, which trigger itching and skin barrier breakdown. Vtama reduces both sets of signals.
Because it is not a steroid, Vtama does not carry the risks associated with long-term steroid use, such as skin thinning. This is a meaningful distinction for people who need ongoing topical treatment on sensitive areas like the face, skin folds, or anywhere that thins easily with repeated steroid exposure.
How Well It Works for Psoriasis
Vtama’s effectiveness in plaque psoriasis was established in two large clinical trials involving over 1,000 adults. Each trial compared the cream to a vehicle (a moisturizer base with no active ingredient) over 12 weeks. The primary measure was the proportion of patients who achieved clear or almost clear skin with meaningful improvement from their starting point.
In the first trial, 35% of patients using Vtama reached clear or almost clear skin at 12 weeks, compared to 6% using the vehicle cream. In the second trial, the results were slightly better: 40% versus 6%. Both differences were statistically significant, meaning the improvement was clearly driven by the medication rather than chance.
One of Vtama’s more distinctive features is what happens after you stop using it. In a long-term follow-up study, about 41% of patients achieved completely clear skin at least once during extended treatment. Among those patients, the average time their skin stayed clear after stopping the cream was roughly 4 months. This “remittive effect” is unusual for a topical treatment, where symptoms typically return quickly once you stop applying the product.
Use in Atopic Dermatitis
For eczema, Vtama was tested in two trials (called ADORING 1 and ADORING 2) involving over 800 adults and children aged 2 and up. Treatment lasted up to 8 weeks. The approval for this younger age group makes Vtama one of the few non-steroidal topical options available for children with eczema, a condition that frequently begins in early childhood and often requires years of management.
Common Side Effects
The most frequently reported side effect is folliculitis, an inflammation of hair follicles that can look like small red bumps or pimples near the application site. In the psoriasis trials, folliculitis occurred in 20% of people using Vtama, compared to just 1% using the vehicle cream. That’s a notable rate, though most cases were mild. Contact dermatitis, a localized skin reaction with redness or irritation, occurred in about 7% of psoriasis patients using Vtama.
In the eczema trials, folliculitis was less common, affecting about 9% of Vtama users versus 1% on the vehicle. Contact dermatitis did not appear as a common reaction in the eczema studies.
Folliculitis from Vtama tends to develop near the treated areas and is generally manageable. If it becomes bothersome, your dermatologist can help you weigh whether the skin-clearing benefits outweigh the irritation. For many people, the folliculitis is mild enough that they continue treatment without issue.
How Vtama Fits Among Other Treatments
For decades, topical steroids have been the default first-line treatment for both psoriasis and eczema. They work well short-term but come with limitations: skin thinning, stretch marks, and rebound flares when stopped abruptly, especially on the face and body folds. Other non-steroidal options exist, such as calcineurin inhibitors for eczema or vitamin D analogs for psoriasis, but each has its own trade-offs in effectiveness and tolerability.
Vtama fills a gap as a steroid-free cream that works through a completely different pathway. Its once-daily application is straightforward, and the potential for a lasting remittive effect after stopping treatment sets it apart from most topical therapies. It is particularly worth discussing with a dermatologist if you have been relying on steroids for extended periods, need treatment on sensitive skin areas, or have not responded well to other topical options.